Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques
- 6 April 2019
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 44 (8) , 1485-1493
Abstract
Trace amine-associated receptor 1 (TAAR1) is a G-protein coupled receptor with affinity for the trace amines. TAAR1 agonists have pro-cognitive, antidepressant-, and antipsychotic-like properties in both rodents and non-human primates (NHPs). TAAR1 agonism also increases wakefulness and suppresses rapid-eye movement (REM) sleep in mice and rats and reduces cataplexy in two mouse models of narcolepsy. We investigated the effects of TAAR1 agonism in Cynomolgus macaques, a diurnal species that exhibits consolidated night-time sleep, and evaluated the effects of TAAR1 agonists on cognition using a working memory (WM) paradigm in this species. Adult male Cynomolgus macaques (n = 6) were surgically implanted to record the electroencephalogram (EEG), electromyogram, and locomotor activity (LMA) and the efficacy of the TAAR1 partial agonist RO5263397 (0.1,1,10 mg/kg, p.o.) on sleep/wake, EEG spectra, and LMA was determined. In a second experiment, the acute effects of RO5263397 (0.1,1,10 mg/kg, p.o.) were assessed on a delayed-match-to-sample test of WM in adult male macaques (n = 7). RO5263397 (10 mg/kg) administered at lights off, when sleep pressure was high, promoted wakefulness and reduced both REM and non-REM sleep without inducing hyperlocomotion. RO5263397 (10 mg/kg) also increased delta/theta activity during all vigilance states. RO5263397 had no effect on WM at either short (2 sec) or long (10 sec) delay intervals. The wake-enhancing and REM-suppressing effects of R05263397 shown here in a diurnal primate are consistent with previous results in nocturnal rodents. These effects and the associated alterations in EEG spectra occurred without inducing hyperlocomotion or affecting WM, encouraging further study of TAAR1 agonists as potential narcolepsy therapeutics.Keywords
Funding Information
- DH | NIHR | Efficacy and Mechanism Evaluation Programme (R21NS085757)
- U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R21NS085757, R01NS103529)
This publication has 44 references indexed in Scilit:
- Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 ReceptorMolecular Pharmacology, 2011
- TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activityProceedings of the National Academy of Sciences, 2011
- The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic systemProceedings of the National Academy of Sciences, 2009
- NMDA Receptor Hypofunction Leads to Generalized and Persistent Aberrant γ Oscillations Independent of Hyperlocomotion and the State of ConsciousnessPLOS ONE, 2009
- A non-invasive technique to monitor wakefulness during electrophysiologic recording experiments in primatesJournal of Neuroscience Methods, 2009
- N-methyl-d-aspartic acid receptor antagonist–induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophreniaNeuroscience, 2009
- Trace amine-associated receptor 1—Family archetype or iconoclast?Pharmacology & Therapeutics, 2007
- Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaquesPsychopharmacology, 2007
- Trace Amine-Associated Receptor 1 Is a Modulator of the Dopamine TransporterThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Facilitation of Task Performance and Removal of the Effects of Sleep Deprivation by an Ampakine (CX717) in Nonhuman PrimatesPLOS Biology, 2005